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Summary Tumour-associated monoclonal antibodies (HMFG1, HMFG2 and AUAI) radiolabelled with
iodine-131 were given intracavitary (intrapleurally and intrapericardially) to patients with malignant effusions.
Ten out of 13 effusions (3 pericardial and 7 pleural) responded completely with no fluid reaccumulation
between 3 and 18 months. No clinical or other toxicity was observed.
This new method of treatment for recurrent malignant effusions is non-toxic and effective resulting in
improved quality of life, and, in some cases, prolongation of survival.
Recurrent pleural or pericardial effusion is a
frequent problem seen in patients with various
forms of cancer, particularly of lung, breast or
ovarian origin (Anderson et al., 1974; Wallach,
1975; Paladine et al., 1976). The aetiology of the
effusion is thought to be due to secondary
metastatic pleural or pericardial implants although
negative fluid cytology may occur with pleural or
pericardial tumour found only at autopsy
(Paladine et al., 1976). Sometimes, autopsy reveals
only mediastinal or parenchymal involvement, and
the effusion is thought to be secondary to
lymphatic blockage (Paladine et al., 1976).
Radioactive isotopes, external beam radio-
therapy, intracavity tetracycline, bleomycin and
alkylating agents have all been used as forms of
palliation with some success. Unfortunately, com-
plications such as pain and rigours can occur and
also there is reaccumulation of serous fluid in many
cases (Strober et al., 1973; Anderson et al., 1974;
Wallach, 1975; Paladine et al., 1976; Ostrowski &
Halsall, 1982).
In previous studies we found that the majority of
malignant serous effusions secondary to epithelial
origin tumours contain neoplastic cells expressing
tumour-associated antigens detected by monoclonal
antibodies HMFG1, HMFG2 and AUA1 (Epenetos
et al., 1982a).
Recently, a new therapeutic method termed
'regional antibody guided irradiation' was
introduced where two patients, one with a
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malignant pleural effusion and one with a
malignant pericardial effusion were treated by the
intracavitary administration of iodine-131 labelled
monoclonal antibody (HMFG2) with encouraging
results (Epenetos et al., 1984). This prompted us to
perform a larger clinical study in order to extend
and confirm our previous preliminary results.
Patients and methods
Eleven consecutive and unselected patients, (5 male
and 6 female; mean age 53 years, range 30-73) were
entered in this study. Four patients had lung cancer
(3 adenocarcinomas, 1 squamous cell carcinoma), 3
ovarian carcinoma, 2 breast carcinoma, 1 prostatic
carcinoma and 1, pancreatic carcinoma. Three had
pericardial effusions and 10 had pleural effusions.
One patient with squamous cell carcinoma of the
lung had both pericardial and pleural effusion, and
1 with ovarian carcinoma had bilateral pleural
effusions. All patients had measurable and
persistent disease following previous chemotherapy
and/or radiotherapy.
Monoclonal antibodies
Monoclonal antibodies HMFG1, HMFG2 and
AUA1 are not tumour specific but, because of their
high reactivity with carcinomas, can be described as
tumour associated.
HMFGJ, HMFG2: These two mouse IgGI
antibodies were raised against a delipidated
preparation of the human milk fat globule. Both
antibodies have a broad spectrum of reactivity with
epithelial origin neoplasms, particularly carcinomas
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of breast, ovary, bronchus, cervix and gastro-
intestinal tract (Arklie et al., 1981).
AUAI: This mouse IgGi is directed against an
epithelial surface antigen found on some normal
epithelia, for example in the colon as well as a wide
range of carcinomas including those of colon,
breast, bronchus and ovary (Epenetos et al., 1982b).
Antibody guided studies
These were conducted in two parts. In part 1,
pleural effusions were tapped as near to dryness as
possible and 1 mCi of radiolabelled antibody was
administered by intracavitary injection and washed
in with 500ml of normal saline in patients with
pleural effusions and 20ml of normal saline in
patients with pericardial effusions. Gamma camera
scans were taken daily, from immediately after
injection up to 7 days afterwards in order to
calculate the dose of radiation that could be
delivered.
In part 2, a higher dose of radiolabelled antibody
was given by the intracavitary route as a
therapeutic attempt. Patients were kept in a single
room for radio protection until their body radio-
activity was below 30mCi. Prior to antibody
studies, patients were given potassium iodide
120mg per day starting one day before part 1, and
continuing for 21 days after part 2.
Dosimetry
When using radiolabelled antibodies for the treat-
ment of serous effusions it is important to have
data on the delivered radiation both to tumour and
normal organs. For effective dosimetry it is
essential to know the activity at the site, the time
course of the activity, the volume of target and the
type of radiation emitted by the radionuclide. These
data can then be incorporated into a standard
formula (Snyder et al., 1978) to produce an
answer that although of limited accuracy would be
sufficiently useful to judge if the therapeutic
procedure were worthwhile or not.
To obtain this a conventional gamma camera
was used after calibration with relatively simple
phantoms and a small range of calibration factors
(Myers et al., 1981). Also a rectilinear scanner with
low sensitivity high resolution collimators to image
the whole body had been used in the first few days
after therapy. The difficulties and limitations of this
approach stem from the poor spatial resolution of
the camera and the inability to measure accurately
the tumour volume. For example, activities
distributed in volumes of 1mm3 or 1cm3 would
appear as having the same area in the image. This
degree of inaccuracy would have a drastic effect on
dosimetry since knowledge of the activity per gram
is essential. Therefore, the doses quoted in Table I
although they are relatively accurate for normal
organs are to be considered inaccurate with regard
to tumour doses, the error being in the range of
+50%. Accurate tumour doses from antibody-
guided irradiation can only be established when
dosimetry at the cellular level becomes feasible.
Immunocytochemistry
Smears of cells from serous effusions were
examined in an indirect immunoperoxidase reaction
for antibody reactivity. The antibody/antibodies
with highest reactivity was/were selected for use
(Epenetos et al., 1982a). Immunocytochemistry was
considered to be positive when >50% of neoplastic
cells stained with at least one antibody. This was
the case with all patients except one (JO).
Radiolabelling
Iodine-131 was added to antibody and iodination
was carried out in iodogen tubes (Fraker & Speck,
1978). The labelled antibody was separated from
free iodine-131 using gel filtration (Sephadex G-50).
Specific activity was in the range of 4-8mCimg-'.
There was no detectable loss of antibody immuno-
reactivity after iodination as tested by ELISA and
direct radioimmunoassay, including competition
with unlabelled antibody. Samples of radiolabelled
antibody were tested for antibody aggregation by
gel filtration. There was no evidence of aggregate
formation. Prior to patient administration radio-
labelled material was millipore filtered and diluted
in 1% human serum.
Results
Ten out of 13 effusions (7 pleural and 3 pericardial)
responded favourably to antibody treatment with
no reaccumulation of fluid (except for minimal
residual fluid), followed up to between 3 and 18
months (mean 7 months) after treatment (Table I).
Repeated examination of fluid was performed on 2
patients who gave prior written informed consent.
Immunocytology was positive for antibodies
HMFG1 and AUA1 before treatment and negative
after treatment.
All 3 patients with malignant pericardial
effusions responded completely to antibody
therapy, with no fluid re-accumulation after 3, 12
and 18 months respectively. Three patients failed to
respond to antibody therapy. One patient had an
effusion secondary to adenocarcinoma of lung, and
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AUA1 antibody. Another patient had a large and
recurrent effusion secondary to carcinoma of
prostate. He was treated empirically with 21 mCi of
iodine-131 labelled HMFG2 antibody without prior
immunocytochemical analysis (there were
insufficient malignant cells in the fluid for immuno-
cytochemistry). It was interesting that when his
recurrent effusion was examined immunocyto-
chemically, malignant cells were negative for the
presence of HMFG2 antigen. It is now known that
the majority of prostate carcinomas do not express
HMFG2 antigen. One patient had a bilateral
pleural effusion, secondary to an ovarian
carcinoma. Left pleural effusion was treated with
30mCi of a mixture of HMFG2 and AUA1
antibody, and it recurred two months after
treatment. Right pleural effusion was treated with
56mCi of iodine-131 labelled HMFG2 antibody
and has not recurred (follow up 6 months). Nine
patients were treated with HMFG2 labelled
antibody, 2 with AUA1, 1 with a combination of
HMFG2 and AUA1 and 1 with HMFG1, HMFG2
and AUA1 monoclonal antibodies. Three out of 3
pericardial effusions and 7 out of 10 pleural
effusions responded completely.
The doses for thyroid ranged from 0.05 to 30Gy;
the explanation for this is that some patients did
not have thyroid blockade with potassium iodide
and some patients despite taking potassium iodide
had some thyroid uptake of free iodine-131. For
effective thyroid blockade, we now recommend
potassium iodide 120mg per day starting 3 days
before the procedure and taking it for a month.
Also potassium perchlorate 400mg should be taken
as a single dose at the time of the procedure.
Discussion
One of the complications of advanced malignant
disease is fluid accumulation in serous cavities. The
rate of production varies but in most instances it
steadily increases requiring shorter and shorter
intervals in the removal of fluid. The intracavitary
instillation of colloidal suspensions of radioisotopes
is an attempt to control the problem and this
approach has been widely used in the past (for
review see Hilton et al., 1957) with good results
obtained in nearly half the cases.
We have previously shown that the intravenous
route of antibody administration leads only to a
very small uptake by tumour cells (average 10-3%
of the injected amount g-1 tumour) (Epenetos,
1983) and this is the reason why we explored other
routes, for example intracavitary administration
(Epenetos et al., 1984).
It was our opinion that the better response
observed with pericardial effusions was due to the
higher dose delivered to pericardium and malignant
cells as compared to doses to pleural cavities and
malignant cells. It was of interest that in the one
patient with bilateral pleural effusions (PB) the one
effusion treated with 30mCi of activity recurred
whilst the other effusion treated with 56mCi of
activity did not recur. Nevertheless in other patients
(EC, LC, JA) there was a satisfactory remission
achieved with doses of - 30mCi. Therefore, two
contributing factors for the outcome of antibody
guided-irradiation appear to be (a) the tumour bulk
and (b) the delivered dose of iodine-131. From our
data, it is suggested that for effective palliation,
30mCi of iodine-131 labelled antibody should be
given intrapericardially and 60mCi intrapleurally.
This study demonstrates that this new method of
treatment of serous effusions is both relatively non-
toxic and effective in relieving fluid accumulation
and improving the quality of life in patients with
advanced malignant disease. At least in one patient
(LC) there was prolongation of survival with the
patient being alive 2 years after antibody treatment
of his pericardial and pleural effusions. It is well
known that non-specific agents such as colloidal
radioactive phosphorus or other substances such as
bleomycin or tetracycline can sometimes be of value
in controlling fluid accumulation. The efficacy of
this method (10 out of 13 responses) appears,
however, superior to previously reported methods
(Paladine et al., 1976; Wallach et al., 1975; Strober
et al., 1973). Nevertheless, our data at present are
not conclusive with regard to the superiority of this
method over previous techniques. What is clear,
however, is that no patient experienced any toxicity
attributable to this therapy. The fact that in one of
the three cases where there was fluid reaccumula-
tion the malignant cells were either negative or only
weakly positive against the administered antibody,
indicates that this new method of treatment may
act via specific antigen antibody interaction. Also it
highlights potential problems that may arise from
antibody therapy such as antigen modulation or
emergence of new phenotypes of malignant cells. A
randomised study is required to establish con-
clusively the efficacy and the mode of action of this
novel therapeutic approach.
We are grateful to: J. Burchell, A. Cross, K.E. Halnan, J.
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